...single seven-gene signature, trained it on the PADIMAC data, and applied it to the 109 bortezomib-treated patients within CoMMpass. Predicted good responders had superior survival to the remaining patients (p=0.016; Figure 1A)....a seven-gene RNAseq signature that can predict if newly diagnosed myeloma patients would benefit from initial bortezomib-based or lenalidomide-based therapy, both in terms of response and survival.